Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 15/20 | 0.67 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20351362 | 0.85 | DUT (0.64) | DUT | |
| SCHEMBL20189654 | 0.84 | DUT (0.70) | DUTKAT6A | |
| SCHEMBL23996253 | 0.81 | DUT (0.44) | DUTKAT6AEPHX2 | |
| SCHEMBL18379994 | 0.81 | DUT (0.68) | DUTKAT6A | |
| SCHEMBL12629721 | 0.80 | DUT (0.67) | DUTKAT6A | |
| SCHEMBL12629736 | 0.78 | DUT (0.75) | DUT | |
| SCHEMBL24153933 | 0.71 | DUT (0.43) | DUTKAT6A | |
| SCHEMBL21690618 | 0.71 | DUT (0.65) | DUT | |
| SCHEMBL21536598 | 0.71 | DUT (0.70) | DUT | |
| SCHEMBL12630200 | 0.70 | DUT (0.56) | DUTKAT6AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562860-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-02-18 | — | — | US | disclosed |
| US-20180194736-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194736-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | DUT 1/4885KAT6A 1511/4885EPHX2 470/4885 |
| US-10562860-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | DUT, TYMP, DPYD | DUT 1/4885KAT6A 1511/4885EPHX2 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.